Self-Study: Selective Androgen Receptor Modulators (SARMs): What Sports RDs Need to Know

Current Status
Not Enrolled
Get Started

In this FREE web-based self-study,  Jeff Novitzky, Dr. James Dalton and John Travis provide in-depth look at the science of SARMs, the testing and prevalence of SARMs in supplements and our food supply.

Course Objectives:
- Explain and identify what a SARMs is and discus the intent behind their invention.
- Describe the effect SARMs could have on an athlete’s health and performance.
- Identify real life examples of how SARMs are being misused and show up in supplements and foods leading to positive drug tests.
- Recite advice for navigating foods and supplements reviews to keep athletes safe.



American Sports and Performance Dietitians Association (Accredited Provider CP294) is approved by the Commission on Dietetic Registration to provide continuing education to Registered Dietitians. This program is eligible for 1.25 CPEU.  The entire couse including the learner's assessment, course evaluation and Critical Thinking Tool must be completed to receive the CDR certificate.  Additionally, feedback on the quality of the activity content can be sent directly to CDR ([email protected]).


Presenter Bios:

Jeff Novitzky has been a federal agent for the United States Food and Drug Administration (FDA) since 2008, led investigations into companies suspected of illegal distribution of dietary supplements and designer steroids.. Prior to joining the USFDA, Novitzky was a special agent for the Internal Revenue Service in their Criminal Investigation Department, where he oversaw and investigated some of the highest-profile performance enhancing drug (PED) cases in professional sports. A former collegiate athlete who played basketball for San Jose State University from 1989-91, Novitzky graduated with a degree in accounting.

Dr. James Dalton became Dean and Professor of Pharmaceutical Sciences in the College in September 2014.  He previously served as Assistant and Associate Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee (1992-2000), Associate Professor, Professor and Chair in the Division of Pharmaceutics in the College of Pharmacy at The Ohio State University (2000-2008), and Vice President of Preclinical Research and Development and Chief Scientific Officer at GTx, Inc. (2005-2014).  Dr. Dalton has no disclosures to report.

John Travis  has more than 20 years of experience in analysis of target analytes and method development, utilizing techniques such as gas and high-performance liquid chromatography and mass spectrometry. He analyzes hundreds of dietary supplement products each year for various contaminants, emerging drugs and harmful compounds. His expertise in the analysis of prohibited substances in dietary supplements was instrumental in developing screening methods for the Certified for Sport® program. John has a degree in chemistry from the University of Michigan. He sat on the AOAC Presidential Task Force on Dietary Supplements and on several review panels. Mr. Travis has not disclosures to report.

Course Bibliography:

Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294–305. doi:10.1159/000356760

Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12(3):232–240. doi:10.1097/MCO.0b013e32832a3d79

Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–161. doi:10.1007/s13539-011-0034-6

Wu D, Wu Z, Yang J, Nair VA, Miller DD, Dalton JT. Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metab Dispos. 2006;34(3):483–494. doi:10.1124/dmd.105.006643

Kearbey JD, Gao W, Narayanan R, et al. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res. 2007;24(2):328–335. doi:10.1007/s11095-006-9152-9